Last reviewed · How we verify
Topiramate Standard
Topiramate blocks sodium channels and enhances GABA-mediated inhibition in the central nervous system to reduce neuronal excitability.
Topiramate blocks sodium channels and enhances GABA-mediated inhibition in the central nervous system to reduce neuronal excitability. Used for Epilepsy / seizure disorders, Migraine prophylaxis, Bipolar disorder (off-label).
At a glance
| Generic name | Topiramate Standard |
|---|---|
| Sponsor | Janssen Korea, Ltd., Korea |
| Drug class | Anticonvulsant / Antiepileptic agent |
| Target | Voltage-gated sodium channels, GABA-A receptors, carbonic anhydrase |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Topiramate is a sulfamate-substituted monosaccharide that acts through multiple mechanisms: it blocks voltage-gated sodium channels, potentiates GABA-A receptor activity, and inhibits carbonic anhydrase. These combined effects reduce neuronal firing and synaptic transmission, making it effective for seizure suppression and migraine prevention.
Approved indications
- Epilepsy / seizure disorders
- Migraine prophylaxis
- Bipolar disorder (off-label)
Common side effects
- Cognitive impairment / memory problems
- Paresthesia
- Weight loss
- Fatigue
- Dizziness
- Acute myopia / angle-closure glaucoma
Key clinical trials
- Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease (PHASE4)
- Metabolic Surgery for Atrial Fibrillation Elimination (PHASE4)
- Combining a Smartphone App With Medications to Manage Heavy Drinking (NA)
- Anti-obesity Pharmacotherapy and Inflammation
- Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW) (PHASE4)
- Medications After Adolescent Bariatric Surgery (PHASE2)
- Adjunct Phentermine + Topiramate After Bariatric Surgery in 12-24 Year Olds (PHASE2)
- Gastric Sleeve-Induced Weight Loss on Shortness of Breath in Obesity (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |